Genomic test used to determine the risk of recurrence in women with breast cancer.
Using the NanoString nCounter® Dx technology and the PAM50 genetic signature analysis algorithm, it is the only test that allows classifying the intrinsic subtype of the breast tumor, as well as establishing a risk category based on the probability of recurrence (ROR) at 10 years. To do this, it considers, together with the molecular information, clinical variables such as the tumor size and the lymph node status of the patient.
The reliability of Prosigna is guaranteed:
- Clinical trials in the US and Spain show that it is a reproducible, accurate and robust test.
- Genomic study with CE marking and approved by the FDA
When is it indicated?
As a prognostic indicator in postmenopausal women with breast cancer undergoing mastectomy surgery, or with breast conservation therapy together with regular locoregional treatment, under the following conditions:
- Patients with hormone receptor-positive tumors and negative lymph nodes in stages I and II, who will be treated with adjuvant endocrine therapy.
- Patients with hormone receptor-positive tumors and positive lymph nodes in stages II and IIIA, who will be treated with adjuvant endocrine therapy.